Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Somatostatin and its related peptide cortistatin exert multiple biological actions on normal and tumoral tissue targets by interacting with somatostatin receptors (SSTRs). Additionally we are shipping SSTR5 Kits (4) and SSTR5 Proteins (4) and many more products for this protein.
Showing 10 out of 55 products:
Combination treatment increased both SSTR2 (show SSTR2 Antibodies) and SSTR5 mRNA and protein levels in DU-145 cells. The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic Prostate cancer (PCa (show FLVCR1 Antibodies)) do not respond to androgen deprivation.
A truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
SSTR5 was the predominantly expressed receptor subtype in the cytoplasm of all GH-secreting adenomas tested, regardless of whether they came from octreotide-naive, octreotide-responsive, or octreotide-resistant patients. SSTR5 mRNA predominance was significant only in octreotide treated patients. Its expression was not correlated with baseline or post-octreotide GH or IGF-1 (show IGF1 Antibodies) levels or tumor volume.
Data showed that the distribution of somatostatin (show SST Antibodies) receptor (SSTR (show SSTR3 Antibodies)) subtypes among the 199 pancreatic neuroendocrine tumors (PNETs) was: SSTR2 (show SSTR2 Antibodies) (54.8%), SSTR1 (show SSTR1 Antibodies) (53.3%), SSTR4 (show SSTR4 Antibodies) (51.8%), SSTR5 (33.7%), and SSTR3 (show SSTR3 Antibodies) (28.6%).
Data indicate that somatostatin (show SST Antibodies) receptor scintigraphy (SRS (show SMS Antibodies)) and immunohistochemical results for somatostatin (show SST Antibodies) and dopamine receptors sstr2 (show SSTR2 Antibodies), sstr3 (show SSTR3 Antibodies), sstr5 and D2R (show DRD2 Antibodies) were compared in neuroendocrine neoplasms tissues.
Somatostatin (show SST Antibodies) receptors were expressed in a high proportion of merkel cell carcinomas, although expression was heterogeneous between tumours and was not associated with disease severity.
An immunohistochemical investigation of the expression of somatostatin (show SST Antibodies) receptor subtypes
SSTR2 (show SSTR2 Antibodies) and SSTR5 protein levels were induced as compared to any agent alone.
SSTR 5 was shown to be the main receptor subtype in the analysed differentiated or anaplastic thyroid malignancies, whereas SSTR 2 (show SSTR2 Antibodies) was found only in a small percentage.
A truncated sst5-variant (sst5TMD4) can influence the secretory response of somatotropinomas to somatostatin (show SST Antibodies) analogues-therapy.
The expression and localization of the three receptors (SSTR3 (show SSTR3 Antibodies)-SSTR5) in wild-type (WT), single-knockout (SSTR1 (show SSTR1 Antibodies) KO) and double-knockout SSTR1 (show SSTR1 Antibodies)/SSTR2 (show SSTR2 Antibodies) (DKO) mice, are reported.
mouse somatostatin receptor 5 is sorted by a network of PDZ-domain (show INADL Antibodies) containing proteins
Findings suggest that somatostatin (show SST Antibodies) and its receptors (SSTR2 (show SSTR2 Antibodies) and SSTR5) are important markers in the regulation and development of Sertoli cell.
In comparison to wt, ApoD (show APOD Antibodies)(-/-) mice exhibit increased SSTR5-like immunoreactivity in paraventricular nuclei and decreased receptor expression in ventromedial hypothalamus and arcuate nucleus.
Somatostatin (show SST Antibodies) inhibited GIP (show GIP Antibodies) and glucagon-like peptide-1 (GLP-1 (show GCG Antibodies)) secretion from primary small intestinal cultures, in part through SSTR5.
SSTR5 is a negative regulator for PDX-1 (show PDX1 Antibodies) expression and SSTR5 may mediate the inhibitory effects of somatostatin (show SST Antibodies) and its analogs on insulin (show INS Antibodies) expression/secretion and cell proliferation via down-regulating PDX-1 (show PDX1 Antibodies)
SST (show SST Antibodies) and SSTRs might play an important role in regulation of neurodegeneration
The existence of new truncated sst5-variants with unique ligand-selective signaling properties, which could contribute to further understanding the complex, distinct pathophysiological roles of somatostatin (show SST Antibodies) and cortistatin (show CORT Antibodies).
Extraovarian somatostatin (show SST Antibodies), acting through its receptors 2 and 5 present on granulosa cells, may be involved in mouse folliculogenesis by reducing recruitment of resting follicles.
The effect of sst2 (show SSTR2 Antibodies) receptor knockout on sst5 receptor mRNA localization and binding sites throughout the brain has been determined.
This study describes the cloning and characterization of procine sst5 and identifies two spliced variants with six and three transmembrane domains (TMD (show TTN Antibodies)): psst5TMD6 and psst5TMD3; psst5TMD6 and psst5TMD3 are functional (e.g., activate calcium signaling.
Data demonstrate that urotensin II (show UTS2 Antibodies) and urotensin II-related peptide directly activate somatostatin (show SST Antibodies) receptors 2 and 5 and thus mimic the effect of somatostatin (show SST Antibodies) on its cognate receptors.
Somatostatin and its related peptide cortistatin exert multiple biological actions on normal and tumoral tissue targets by interacting with somatostatin receptors (SSTRs). The protein encoded by this gene is one of the SSTRs, which is a multi-pass membrane protein and belongs to the G-protein coupled receptor 1 family. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase, and different regions of this receptor molecule are required for the activation of different signaling pathways. A mutation in this gene results in somatostatin analog resistance. Alternatively spliced transcript variants have been identified in this gene.
somatostatin receptor type 5
, somatostatin receptor 5
, somatostatin receptor subtype 5
, Somatostatin receptor subtype 5